Novo Plunges as Investors Seek More Robust Sales Targets
Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround…
Read the full story at Bloomberg Markets ↗
ImpactNotable 49/100
Why it mattersRule-based estimate: event keywords (+12); trust 9/10.
RegionsGlobal
Published2 h ago (Mon, 21 Sep 2026 09:26:25 GMT)
RetrievedMon, 21 Sep 2026 10:00:52 GMT via rss
ClassifiedMon, 21 Sep 2026 10:01:09 GMT by heuristic